Novo Nordisk A/S, NVO is in the exchange NYSE and its industry is Drug Manufacturers – Other in the sector of Healthcare. Based in Denmark, Novo Nordisk A/S, NVO has a market cap of 109832.56. Since its IPO date on the 1/4/1982, Novo Nordisk A/S, NVO performance year to date is -4.40%. Today Novo Nordisk A/S, NVO has gained 1.17%, with a current price of 55.2.
Ownership of the company is 26.40% for insider ownership while institutional ownership is 10.30%. The management of the company have seen the company have a payout ratio of 47.50%. Return of assets are at 40.40%, with return on investment at 85.00%.
In terms of debt levels and profit levels, Novo Nordisk A/S, NVO is seeing a long-term debt/equity of 0. While Total debt/equity is 0.01. With a profit margin of 31.30%, this is combined with a gross margin of 84.90%, and operating margin of 43.60%. Novo Nordisk A/S ability to meet debt levels, with a current ratio of 1.1, while the quick ratio is 0.8.
For the last year Novo Nordisk A/S, NVO has seen a EPS growth of 34.30%. A performance for the year of 1.38%. The 52-week high is -6.90%, and the 52-week low is 21.67%. The average volume for Novo Nordisk A/S, NVO is 12543.
With a target price of 60.1, can Novo Nordisk A/S, NVO reach this target? Looking at the value indicators of Novo Nordisk A/S, NVO. Novo Nordisk A/S has a P/E of 27.32 and a forward P/E of 22.14. Perhaps the more useful indicator than P/E, is PEG which has a value of 2.34. Novo Nordisk A/S also has a P/S and a P/B of 6.72 and 25.03 respectively. For P/cash, Novo Nordisk A/S has a value of 83.47, while it is 39.56 for P/free cash flow.
At the current price of 55.2, Novo Nordisk A/S has a dividend yield of 1.76%. We see a return on equity of 82.70%.
Looking more long-term Novo Nordisk A/S, is projected to get an EPS growth for the next five years of 11.70%. In the short-term an EPS growth of 8.40% in the next year is forecasted. This is after a EPS growth of 34.30% for this year and for the last five years a 22.40% growth has been seen.